In Norway, the Nordic protocol NOPHO (Nordic Society for Pediatric Hematology and Oncology) AML 2004 is followed for treating AML. The exception is children with Down's syndrome who should be treated with the European protocol ML-DS 2006 according to NOPHO's AML working group. This protocol is not formally approved in Norway, but resembles the NOPHO-AML protocol and is used as "best available treatment."
For acute promlyelocyte leukemia (APL, M3-AML), NOPHO’s AML group uses the international protocol ICC APL study 01 as "best available treatment.”
Drug therapy for AML is divided into 6 courses of chemotherapy.
- Acute myelogenous leukemia
- Control the disease on a hematological, cytogenetic, and molecular level